SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act
Date of Report (Date of earliest event reported)
LEXARIA BIOSCIENCE CORP.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of
(Commission File Number)
156 Valleyview Road, Kelowna, BC Canada
(Address of principal executive offices)
Registrants telephone number, including area code
(Former name or former address, if
changed since last report.)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ] Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
[ ] Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e -4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b -2
of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act.
3.02 Unregistered Sales of
Lexaria has received US$6,733.02
from the exercise of a
compensation option certificate previously granted. The compensation option
certificate was exercised at the price of US$0.42 and a total of 16,031 common
shares are being issued. This exercise is by a third party who is neither an
officer nor a director of the Company. The Company has also issued 8,016 warrants with
an exercise price of US$0.60 and an expiration date of April 3, 2019, related to
the compensation option certificate.
- 2 -
Lexaria is issuing 14,634 restricted common shares at an
issuance price of US$0.82 per shares to settle US$12,000 of debt to a director
of the Company.
Lexaria is granting 200,000 stock options with an exercise
price of US$0.83 and an expiration date of December 1, 2022 to an officer of the
Company, pursuant to an existing management contract. Lexaria is awarding
250,000 stock warrants with an exercise price of US$0.83 and an expiration date
of December 1, 2019 to a manager of the Company, pursuant to a management
Lexaria is awarding a total of 209,056 restricted common shares
at an issuance price of US$0.82 as required by intellectual property performance
thresholds within an existing management consulting contract with the Company
divided between three officers and three managers.
Following issuance of these common shares, Lexaria will have
69,674,919 common shares issued and outstanding. No commissions or placement
fees have been paid related to the funds received from these warrants exercised.
Proceeds will be used for general corporate purposes.
The securities referred to herein will not be or have not
been registered under the United States Securities Act of 1933, as amended, and
may not be offered or sold in the United States absent registration or an
applicable exemption from registration requirements.
7.01 Regulation FD Disclosure
A copy of the news release announcing that Lexaria has received
from the exercise of a compensation option certificate
previously granted is filed as exhibit 99.1 to this current report and is hereby
incorporated by reference.
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
LEXARIA BIOSCIENCE CORP.
CEO, Principal Executive Officer
Date: December 1, 2017